

John R Burnett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2459400/john-r-burnett-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

3,502
citations

32
h-index

55
g-index

131
ext. papers

3,997
ext. citations

5
avg, IF

5.37
L-index

#	Paper	IF	Citations
122	Incidental diagnosis of LPL deficiency in an infant presenting with an acute respiratory infection.. <i>Clinica Chimica Acta</i> , 2022 , 529, 1-1	6.2	
121	Disorders of Lipoprotein Metabolism 2022 , 1035-1055		
120	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). <i>Atherosclerosis</i> , 2021 ,	3.1	3
119	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. <i>Heart Lung and Circulation</i> , 2021 , 30, 372-379	1.8	6
118	Publication metrics: it really is all about the numbers. <i>Pathology</i> , 2021 , 53, 561-563	1.6	0
117	l-asparaginase-induced biochemical toxicities in young adults with acute lymphoblastic leukaemia and T-lymphoblastic lymphoma. <i>Pathology</i> , 2021 , 53, 924-926	1.6	0
116	Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. <i>Journal of Clinical Apheresis</i> , 2021 , 36, 48-58	3.2	0
115	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. <i>Heart Lung and Circulation</i> , 2021 , 30, 324-349	1.8	20
114	The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia. <i>Pathology</i> , 2021 , 53, 288-290	1.6	
113	Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. <i>Annals of Clinical Biochemistry</i> , 2021 , 58, 153-156	2.2	1
112	Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia. <i>Journal of Paediatrics and Child Health</i> , 2021 ,	1.3	1
111	Tangier disease: update for 2020. <i>Current Opinion in Lipidology</i> , 2020 , 31, 80-84	4.4	13
110	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2020 , 298, 52-57	3.1	5
109	Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. <i>Pathology</i> , 2020 , 52, 447-452	1.6	1
108	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. <i>Clinical Genetics</i> , 2020 , 97, 257-263	4	3
107	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. <i>Clinica Chimica Acta</i> , 2020 , 510, 211-215	6.2	7
106	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. <i>Clinical Chemistry</i> , 2019 , 65, 1258-1266	5.5	22

105	Update on the diagnosis, treatment and management of rare genetic lipid disorders. <i>Pathology</i> , 2019 , 51, 193-201	1.6	11
104	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. <i>Pathology</i> , 2019 , 51, 148-154	1.6	49
103	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. <i>Clinical Cardiology</i> , 2018 , 41, 378-384	3.3	23
102	Parent-child genetic testing for familial hypercholesterolaemia in an Australian context. <i>Journal of Paediatrics and Child Health</i> , 2018 , 54, 741-747	1.3	11
101	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 1704-1714	5.6	30
100	The role of patient registries for rare genetic lipid disorders. <i>Current Opinion in Lipidology</i> , 2018 , 29, 156-162	4.6	15
99	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. <i>Current Atherosclerosis Reports</i> , 2018 , 20, 31	6	13
98	Documenting family history in children with hypercholesterolaemia: A lost opportunity. <i>Journal of Paediatrics and Child Health</i> , 2017 , 53, 470-473	1.3	4
97	Clinical utility gene card for: Sitosterolaemia. <i>European Journal of Human Genetics</i> , 2017 , 25,	5.3	9
96	Clinical utility gene card for: Tangier disease. <i>European Journal of Human Genetics</i> , 2017 , 25,	5.3	6
95	Lipoprotein Lipase Deficiency in an Infant With Chylomicronemia, Hepatomegaly, and Lipemia Retinalis. <i>Global Pediatric Health</i> , 2017 , 4, 2333794X17715839	1.2	
94	Filiarial chyluria with nephrotic-range proteinuria and associated hypoalbuminaemia and hypogammaglobulinaemia secondary to bilateral lymphorenal fistulae. <i>BMJ Case Reports</i> , 2017 , 2017,	0.9	0
93	Isolated brachydactyly type E and idiopathic pancreatitis in a patient presenting to a lipid disorders clinic. <i>BMJ Case Reports</i> , 2017 , 2017,	0.9	1
92	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1329-1337.e3	4.9	32
91	Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia. <i>Pathology</i> , 2016 , 48, 463-6	1.6	11
90	EB Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 3732-3739	5.6	17
89	High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. <i>Atherosclerosis</i> , 2016 , 253, 7-14	3.1	17
88	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 275-81	4	8

87	Novel APOB missense variants, A224T and V925L, in a black South African woman with marked hypocholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 604-9	4.9	2
86	Lipoprotein metabolism in an apoB-80 familial hypobetalipoproteinemia heterozygote. <i>Clinical Biochemistry</i> , 2016 , 49, 720-722	3.5	2
85	Lipoprotein lipase deficiency presenting with neonatal perianal abscesses. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	2
84	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. <i>Nature Reviews Endocrinology</i> , 2016 , 12, 467-84	15.2	22
83	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014. <i>European Journal of Human Genetics</i> , 2015 , 23,	5.3	6
82	SPG11 mutation in a Turkish familial hypobetalipoproteinemia family with hereditary spastic paraplegia. <i>Clinica Chimica Acta</i> , 2015 , 445, 1	6.2	
81	Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. <i>Circulation Research</i> , 2015 , 116, 193-205	15.7	44
80	Clinical utility gene card for: Abetalipoproteinaemia--Update 2014. <i>European Journal of Human Genetics</i> , 2015 , 23,	5.3	6
79	Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia. <i>Free Radical Biology and Medicine</i> , 2015 , 88, 59-62	7.8	7
78	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. <i>International Journal of Cardiology</i> , 2015 , 201, 633-8	3.2	55
77	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. <i>Clinica Chimica Acta</i> , 2015 , 448, 18-21	6.2	11
76	Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E1484-90	5.6	6
75	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. <i>Atherosclerosis</i> , 2015 , 239, 93-100	3.1	54
74	HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. <i>Circulation Research</i> , 2015 , 116, 1133-42	15.7	172
73	Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia. <i>Contemporary Endocrinology</i> , 2015 , 251-266		
72	Update on primary hypobetalipoproteinemia. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 423	6	39
71	Novel missense MTTP gene mutations causing abetalipoproteinemia. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014 , 1842, 1548-54	5	21
70	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 387-403	6.5	24

69	Running interference to lower cholesterol. <i>Lancet, The</i> , 2014 , 383, 10-12	40	7
68	Clinical features and genetic analysis of three patients with severe hypertriglyceridaemia. <i>Annals of Clinical Biochemistry</i> , 2014 , 51, 485-9	2.2	10
67	A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemann-Pick disease type B presenting to a lipid disorders clinic. <i>Annals of Clinical Biochemistry</i> , 2014 , 51, 615-8	2.2	2
66	Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2365-73	15.1	48
65	Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. <i>Atherosclerosis</i> , 2014 , 234, 469-72	3.1	21
64	Anti-PCSK9 therapies for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 429-35	5.4	40
63	Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. <i>Clinica Chimica Acta</i> , 2013 , 421, 121-5	6.2	9
62	Recent developments in the genetics of LDL deficiency. <i>Current Opinion in Lipidology</i> , 2013 , 24, 111-5	4.4	11
61	Protein kinase C controls vesicular transport and secretion of apolipoprotein E from primary human macrophages. <i>Journal of Biological Chemistry</i> , 2013 , 288, 5186-97	5.4	15
60	Genetic analysis of familial hypercholesterolaemia in Western Australia. <i>Atherosclerosis</i> , 2012 , 224, 430-4	3.1	56
59	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). <i>European Journal of Human Genetics</i> , 2012 , 20,	5.3	10
58	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. <i>Vascular Health and Risk Management</i> , 2012 , 8, 651-9	4.4	32
57	Anacetrapib, a cholesteryl ester transfer protein inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 103-9	5.9	9
56	Opportunistic screening for familial hypercholesterolaemia via a community laboratory. <i>Annals of Clinical Biochemistry</i> , 2012 , 49, 534-7	2.2	44
55	Clinical utility gene card for: Abetalipoproteinaemia. <i>European Journal of Human Genetics</i> , 2012 , 20,	5.3	30
54	Dalcetrapib , a cholesteryl ester transfer protein modulator. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1427-32	5.9	16
53	Screening for familial hypercholesterolaemia. <i>Pathology</i> , 2012 , 44, 122-8	1.6	23
52	Mipomersen, an antisense apolipoprotein B synthesis inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 265-72	5.9	48

51	Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2011 , 48, 1-18	9.4	50
50	Familial hypercholesterolaemia: a model of care for Australasia. <i>Atherosclerosis Supplements</i> , 2011 , 12, 221-63	1.7	153
49	Genetic determinants of hepatic steatosis in man. <i>Journal of Lipid Research</i> , 2011 , 52, 593-617	6.3	90
48	Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia. <i>Annals of Clinical Biochemistry</i> , 2009 , 46, 420-2	2.2	4
47	A novel missense HGD gene mutation, K57N, in a patient with alkaptonuria. <i>Clinica Chimica Acta</i> , 2009 , 403, 254-6	6.2	9
46	A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. <i>Clinica Chimica Acta</i> , 2009 , 409, 136-9	6.2	13
45	Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. <i>Current Opinion in Molecular Therapeutics</i> , 2009 , 11, 681-91		28
44	Vitamin E in human health and disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2008 , 45, 417-50	9.4	116
43	Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia. <i>Clinica Chimica Acta</i> , 2008 , 390, 152-5	6.2	5
42	High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. <i>Annals of Clinical Biochemistry</i> , 2008 , 45, 170-6	2.2	20
41	Estimating LDL ApoB: infomania or clinical advance?. <i>Clinical Chemistry</i> , 2008 , 54, 782-4	5.5	1
40	Common and rare gene variants affecting plasma LDL cholesterol. <i>Clinical Biochemist Reviews</i> , 2008 , 29, 11-26	7.3	38
39	Phenylketonuria: an inborn error of phenylalanine metabolism. <i>Clinical Biochemist Reviews</i> , 2008 , 29, 31-41	7.3	180
38	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 181-9	6.4	49
37	Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. <i>Journal of Biological Chemistry</i> , 2007 , 282, 24270-83	5.4	58
36	Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1474-8	5.6	28
35	The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. <i>Atherosclerosis</i> , 2007 , 193, 445-8	3.1	271
34	Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. <i>IDrugs: the Investigational Drugs Journal</i> , 2007 , 10, 805-13		13

33	Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. <i>Clinical Chemistry</i> , 2006 , 52, 1339-45	5.5	30
32	Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1337-51	5.9	21
31	New therapies for familial hypercholesterolemia. <i>Expert Opinion on Therapeutic Patents</i> , 2006 , 16, 349-361	6.8	
30	Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. <i>IDrugs: the Investigational Drugs Journal</i> , 2006 , 9, 495-9		
29	Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia. <i>Current Opinion in Investigational Drugs</i> , 2006 , 7, 850-6		8
28	Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. <i>Current Opinion in Molecular Therapeutics</i> , 2006 , 8, 461-7		11
27	The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005 , 1738, 10-8	5	6
26	Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2005 , 42, 515-45	9.4	75
25	Familial hypercholesterolaemia: a look back, a look ahead. <i>Medical Journal of Australia</i> , 2005 , 183, 222-223		
24	Liver dysfunction and steatosis in familial hypobetalipoproteinemia. <i>Clinical Chemistry</i> , 2005 , 51, 266-9	5.5	34
23	Torcetrapib + atorvastatin (Pfizer). <i>Current Opinion in Investigational Drugs</i> , 2005 , 6, 944-50		1
22	"Milky" urine: a case of chyluria. <i>Medical Journal of Australia</i> , 2004 , 180, 89	4	6
21	Lipid disorders and mutations in the APOB gene. <i>Clinical Chemistry</i> , 2004 , 50, 1725-32	5.5	154
20	Lipids, lipoproteins, atherosclerosis and cardiovascular disease. <i>Clinical Biochemist Reviews</i> , 2004 , 25, 2	7.3	22
19	Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. <i>Journal of Lipid Research</i> , 2003 , 44, 943-52	6.3	26
18	A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. <i>Journal of Biological Chemistry</i> , 2003 , 278, 13442-52	5.4	70
17	Eflucimibe. Pierre Fabre/Eli Lilly. <i>Current Opinion in Investigational Drugs</i> , 2003 , 4, 347-51		7
16	FM-VP4 Forbes Medi-Tech. <i>Current Opinion in Investigational Drugs</i> , 2003 , 4, 1120-5		4

15	Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1884-91	9.4	56
14	Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2002 , 39, 89-137	9.4	34
13	Cardiovascular disease and osteoporosis: is there a link between lipids and bone?. <i>Annals of Clinical Biochemistry</i> , 2002 , 39, 203-10	2.2	44
12	Avasimibe Pfizer. <i>Current Opinion in Investigational Drugs</i> , 2002 , 3, 1328-33		2
11	Therapeutic considerations for postprandial dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2001 , 3, 143-56	6.7	6
10	Common and rare ABCA1 variants affecting plasma HDL cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 1983-9	9.4	113
9	The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. <i>Endocrinology</i> , 1999 , 140, 5293-302	4.8	46
8	Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. <i>Clinica Chimica Acta</i> , 1999 , 286, 231-42	6.2	28
7	Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. <i>Journal of Lipid Research</i> , 1999 , 40, 1317-1327	6.3	55
6	Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. <i>Lipids and Lipid Metabolism</i> , 1998 , 1393, 63-79		19
5	The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 1906-14	9.4	29
4	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. <i>Current Opinion in Lipidology</i> , 1997 , 8, 138-45	4.4	85
3	Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 2589-600	9.4	83
2	Familial hypobetalipoproteinaemia: a rare presentation to the lipid clinic. <i>Medical Journal of Australia</i> , 1993 , 159, 272-4	4	6
1	Molecular Genetics of Hypobetalipoproteinaemia and Abetalipoproteinaemia		1